Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 23;403(10432):1133-1136.
doi: 10.1016/S0140-6736(24)00316-7. Epub 2024 Mar 11.

Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign

Marianne Shawe-Taylor  1 , David Greenwood  2 , Agnieszka Hobbs  3 , Giulia Dowgier  3 , Rebecca Penn  2 , Theo Sanderson  2 , Phoebe Stevenson-Leggett  3 , James Bazire  3 , Ruth Harvey  4 ; Crick COVID Serology Pipeline Investigators, Legacy Investigators; Vincenzo Libri  5 , George Kassiotis  6 , Steve Gamblin  2 , Nicola S Lewis  4 , Bryan Williams  7 , Charles Swanton  8 , Sonia Gandhi  8 , Edward J Carr  8 , Mary Y Wu  2 , David L V Bauer  9 , Emma C Wall  10
Affiliations

Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign

Marianne Shawe-Taylor et al. Lancet. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Divergent performance of vaccines in the UK autumn 2023 COVID booster campaign.
(A) Timeline of circulating SARS-CoV-2 variant lineages and the UK COVID-19 vaccination programme. (B) Visualisation of the sequence differences between SARS-CoV-2 variants. Distance scale in amino acids (‘aa’) is indicated, which does not necessarily reflect antigenic distances. (C) Fifth doses administered to participants of the UCLH-Crick Legacy study, coloured by vaccine type as indicated. (D) Serum neutralisation titres comparing pre- and post-fifth dose, grouped by type of fifth dose vaccine received. (Eborj) Serum neutralisation titres following fifth dose vaccination in eligible participants compared between fifth dose vaccine received. In all panels, P-values were determined using unpaired two-tailed Wilcoxon signed-rank tests, and where calculated, the median fold-change (‘FC’) between pre- and post-vaccination titres and the 95% confidence interval (see Methods, Appendix page 10-11) are indicated. An analysis of paired data is shown in Supplementary Figure 1 (Appendix p3).
See this image and copyright information in PMC

References

    1. WHO. Statement on the antigen composition of COVID-19 vaccines. 2023. [accessed Dec 21, 2023]. published online Dec 13 https://www.who.int/news/item/13-12-2023-statement-on-the-antigen-compos....
    1. JCVI. JCVI statement on the COVID-19 vaccination programme for autumn 2023 - update 7 July 2023. Gov uk; 2023. [accessed Dec 20, 2023]. published online Aug 30 https://www.gov.uk/government/publications/covid-19-autumn-2023-vaccinat....
    1. Carr EJ, Wu MY, Gahir J, et al. Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection. Lancet Infect Dis. 2023 doi: 10.1016/S1473-3099(23)00289-X. published online June 5. - DOI - PMC - PubMed
    1. Wu MY, Carr EJ, Harvey R, et al. WHO’s Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed. Lancet. 2022 doi: 10.1016/S0140-6736(22)01938-9. published online Oct 6. - DOI - PMC - PubMed
    1. Owen A, Diaz JV, Guyatt G, et al. WHO Living Guidelines on antivirals for COVID-19 are evidence-based. Lancet. 2022;400:2196–8. doi: 10.1016/S0140-6736(22)02306-6. - DOI - PMC - PubMed

Publication types